お知らせ • Jan 26
ReLive Biotechnologies, Ltd. acquired all operating assets of co.don AG from co.don AG (XTRA:CNW). ReLive Biotechnologies, Ltd. acquired all operating assets of co.don AG from co.don AG (XTRA:CNW) on January 25, 2023. ReLive Biotechnologies, Ltd. completed the acquisition of all operating assets of co.don AG from co.don AG (XTRA:CNW) on January 25, 2023. お知らせ • Aug 26
co.don AG to Report First Half, 2022 Results on Sep 30, 2022 co.don AG announced that they will report first half, 2022 results on Sep 30, 2022 Reported Earnings • Jul 11
Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2021 results: €0.41 loss per share (up from €0.85 loss in FY 2020). Revenue: €10.0m (up 61% from FY 2020). Net loss: €9.32m (loss narrowed 33% from FY 2020). Revenue missed analyst estimates by 100%. Earnings per share (EPS) exceeded analyst estimates by 100%. Over the next year, revenue is forecast to grow 66%, compared to a 31% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 56% per year, which means it is significantly lagging earnings. お知らせ • May 05
co.don AG to Report Fiscal Year 2021 Final Results on Jun 15, 2022 co.don AG announced that they will report fiscal year 2021 final results on Jun 15, 2022 お知らせ • May 02
co.don AG Announces Resignation of Hans-B. Bauerfeind as Chairman of the Supervisory Board for Health Reasons Professor Hans-B. Bauerfeind has informed co.don AG that he is resigning from his chairmanship of the Supervisory Board for health reasons at the age of 81 and is retiring from the Supervisory Board with immediate effect. The office of Chairman of the Supervisory Board will be taken over by Mr. Thommy Stählin, long-time member of the Supervisory Board and former Deputy Chairman of the Supervisory Board. Price Target Changed • Apr 27
Price target decreased to €5.85 Down from €7.60, the current price target is an average from 2 analysts. New target price is 321% above last closing price of €1.39. Stock is down 19% over the past year. The company is forecast to post a net loss per share of €0.37 next year compared to a net loss per share of €0.85 last year. お知らせ • Feb 26
co.don AG Announces Resignation of Hans-Joachim Simons as Member of the Executive Board Effective February 28, 2022 In agreement with the Supervisory Board, Dr. Hans-Joachim Simons has resigned from his position as a member of the Executive Board of CO.DON AG with effect from the end of February 28, 2022, in order to pursue new professional responsibilities. Price Target Changed • Feb 01
Price target decreased to €5.85 Down from €7.60, the current price target is an average from 2 analysts. New target price is 245% above last closing price of €1.69. Stock is down 34% over the past year. The company is forecast to post a net loss per share of €0.37 next year compared to a net loss per share of €0.85 last year. Major Estimate Revision • Aug 07
Consensus EPS estimates fall to -€0.29 The consensus outlook for earnings per share (EPS) in 2021 has deteriorated. 2021 revenue forecast decreased from €11.1m to €10.0m. Losses expected to increase from -€0.21 to -€0.29. Biotechs industry in Germany expected to see average net income decline 12% next year. Consensus price target of €4.20 unchanged from last update. Share price fell 11% to €1.12 over the past week. Price Target Changed • Jun 22
Price target increased to €4.20 Up from €3.80, the current price target is an average from 2 analysts. New target price is 193% above last closing price of €1.44. Stock is up 15% over the past year. お知らせ • Jun 04
co.don Ag Announces Marketing Authorisation Granted for Spherox in the United Kingdom The MHRA (Medicines and Healthcare products Regulatory Agency) has granted marketing authorisation for the autologous medicinal product Spherox marketed by CO.DON AG, thus completing the BREXIT-related transition of the medicinal product, which has already been approved throughout the EU. The regulatory authority MHRA regulates the approval of medicines, medical devices and blood components for transfusions in the UK. The re-approval process had become necessary due to the UK's withdrawal from the European Union, as the scope of the original approval only covered EU member states. Major Estimate Revision • May 27
Consensus forecasts updated The consensus outlook for 2021 has been updated. Forecast loss of -€0.21 per share in 2021, versus previous forecasts of €0.15 per share. Revenue forecast unchanged from €11.1m at last update. Biotechs industry in Germany expected to see average net income growth of 0.4% next year. Consensus price target of €3.80 unchanged from last update. Share price rose 4.9% to €1.07 over the past week. お知らせ • May 22
co.don AG Receives Positive Vote of Committee for Medicinal Products for Human Use of the EMA CO.DON AG received the positive vote of the CHMP (Committee for Medicinal Products for Human Use) of the EMA (European Medicines Agency) on theapproval of the application for the indication extension of the EU-wide approved medicinal product for human use "Spherox - Spheroids from human autologous matrix-associated chondrocytes" for the use in adolescents. The CHMP's assessment is the basis for the European Commission's decision on the EU-wide authorisation of the indication extension. In the past, the European Commission followed the recommendations of the CHMP in the vast majority of applications. With the expanded indication for the EU, the treatment of symptomatic articular cartilage defects of ICRS Grade III or IV of the femoral condyle and the patella of the knee with defect sizes of up to 10 cm ^ 2 is now also possible in adolescents with closed growth plates in addition to adult patients. Reported Earnings • May 06
Full year 2020 earnings released: €0.43 loss per share (vs €0.59 loss in FY 2019) The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: €7.10m (up 2.8% from FY 2019). Net loss: €13.9m (loss widened 9.8% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has fallen by 49% per year, which means it is performing significantly worse than earnings. お知らせ • Apr 29
co.don AG Technology Transfer Process Gets Green Light from EMA The European Medicines Agency has authorized the new manufacturing site in Leipzig for CO.DON AG. The Leipzig site is now formally approved for the manufacture, quality control and marketing of Spherox for the EU. This means that all the official requirements set by the EMA to produce the pharmaceutical product in Leipzig and its distribution within the EU market have been met. The technology transfer process will be completed with a routine inspection by the state authority for Saxony, which The company expects to take place in summer 2021. Spherox production is planned to start in Leipzig in August/September 2021, whereby both sites will initially produce for the EU market in parallel. お知らせ • Dec 19
CO.DON AG Appoints Achim Simons to Executive Board The Supervisory Board of CO.DON AG has appointed Dr. Achim Simons to the Executive Board of CO.DON AG with effect from 1 January 2021. Dr. Simons was previously a surgeon. Is New 90 Day High Low • Oct 13
New 90-day low: €0.95 The company is down 28% from its price of €1.32 on 15 July 2020. The German market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.58 per share. Is New 90 Day High Low • Sep 19
New 90-day low: €0.96 The company is down 23% from its price of €1.24 on 19 June 2020. The German market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €2.63 per share.